Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Defence-Aktie mit Ritterschlag: Regierungs-Einladung zur größten Militärmesse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ERJP | ISIN: US00688A2050 | Ticker-Symbol:
NASDAQ
08.10.25 | 18:37
0,393 US-Dollar
+1,39 % +0,005
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ADIAL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ADIAL PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ADIAL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.09.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04154GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
16.09.Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder2
16.09.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
09.09.ADIAL PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans2
03.09.Adial Pharmaceuticals receives 180-day Nasdaq extension to meet $1 bid price1
03.09.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
03.09.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule1
ADIAL PHARMACEUTICALS Aktie jetzt für 0€ handeln
20.08.Adial Hails Senate Moves on Trials1
20.08.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments114GLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
14.08.Adial Pharmaceuticals reports Q2 results1
14.08.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update153GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
14.08.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
13.08.ADIAL PHARMACEUTICALS, INC. - 10-Q, Quarterly Report1
06.08.Adial Pharmaceuticals completes FDA meeting for alcohol disorder drug2
01.08.Aktionäre von Adial Pharmaceuticals geben grünes Licht für Aktienerhöhung und Vorstandsvorschläge3
01.08.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report2
16.07.Adial Pharmaceuticals regains compliance with Nasdaq stockholders' equity listing requirement4
16.07.Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement212GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
10.07.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report3
09.07.Adial Pharmaceuticals files patent update for alcohol disorder treatment1
Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1